Skip header and navigation

2 records – page 1 of 1.

(18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.

https://arctichealth.org/en/permalink/ahliterature276760
Source
BMC Cancer. 2016;16:10
Publication Type
Article
Date
2016
Author
Randi F Fonager
Helle D Zacho
Niels C Langkilde
Lars J Petersen
Source
BMC Cancer. 2016;16:10
Date
2016
Language
English
Publication Type
Article
Keywords
Bone Neoplasms - pathology - radiography
Denmark
Fluorine Radioisotopes - chemistry
Humans
Male
Multimodal Imaging
Neoplasm Metastasis
Neoplasm Staging
Positron-Emission Tomography
Prostatic Neoplasms - pathology - radiography
Risk factors
Tomography, X-Ray Computed
Abstract
For decades, planar bone scintigraphy has been the standard practice for detection of bone metastases in prostate cancer and has been endorsed by recent oncology/urology guidelines. It is a sensitive method with modest specificity. (18)F-fluoride positron emission tomography/computed tomography has shown improved sensitivity and specificity over bone scintigraphy, but because of methodological issues such as retrospective design and verification bias, the existing level of evidence with (18)F-fluoride positron emission tomography/computed tomography is limited. The primary objective is to compare the diagnostic properties of (18)F-fluoride positron emission tomography/computed tomography versus bone scintigraphy on an individual patient basis.
One hundred forty consecutive, high-risk prostate cancer patients will be recruited from several hospitals in Denmark. Sample size was calculated using Hayen's method for diagnostic comparative studies. This study will be conducted in accordance with recommendations of standards for reporting diagnostic accuracy studies. Eligibility criteria comprise the following: 1) biopsy-proven prostate cancer, 2) PSA = 50 ng/ml (equals a prevalence of bone metastasis of ˜ 50% in the study population on bone scintigraphy), 3) patients must be eligible for androgen deprivation therapy, 4) no current or prior cancer (within the past 5 years), 5) ability to comply with imaging procedures, and 6) patients must not receive any investigational drugs. Planar bone scintigraphy and (18)F-fluoride positron emission tomography/computed tomography will be performed within a window of 14 days at baseline. All scans will be repeated after 26 weeks of androgen deprivation therapy, and response of individual lesions will be used for diagnostic classification of the lesions on baseline imaging among responding patients. A response is defined as PSA normalisation or = 80% reduction compared with baseline levels, testosterone below castration levels, no skeletal related events, and no clinical signs of progression. Images are read by blinded nuclear medicine physicians. The protocol is currently recruiting.
To the best of our knowledge, this is one of the largest prospective studies comparing (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy. It is conducted in full accordance with recommendations for diagnostic accuracy trials. It is intended to provide valid documentation for the use of (18)F-fluoride positron emission tomography/computed tomography for examination of bone metastasis in the staging of prostate cancer.
Notes
Cites: Eur Urol. 2014 Feb;65(2):467-7924321502
Cites: Eur J Cancer. 2014 Oct;50(15):2519-3125139492
Cites: Nat Rev Cancer. 2005 Jan;5(1):21-815630412
Cites: Semin Nucl Med. 2001 Jan;31(1):28-4911200203
Cites: Cancer. 2003 Feb 1;97(3 Suppl):758-7112548573
Cites: Fam Pract. 2004 Feb;21(1):4-1014760036
Cites: Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):BP99-10614989222
Cites: Clin Invest Med. 1982;5(4):267-756819101
Cites: AJR Am J Roentgenol. 1984 Apr;142(4):773-66230903
Cites: J Steroid Biochem. 1985 Nov;23(5B):833-412934579
Cites: Clin Nucl Med. 1990 Jul;15(7):485-72116949
Cites: J Nucl Med. 2006 Feb;47(2):287-9716455635
Cites: BMJ. 2008 May 17;336(7653):1106-1018483053
Cites: Lancet. 2008 May 17;371(9625):1710-2118486743
Cites: BJU Int. 2008 Dec;102(11):1531-819035858
Cites: Allergy. 2009 Aug;64(8):1109-1619489757
Cites: Br J Cancer. 2009 Oct 20;101(8):1225-3219789531
Cites: J Natl Compr Canc Netw. 2010 Feb;8(2):14520141674
Cites: J Urol. 2010 Jul;184(1):162-720483155
Cites: J Clin Epidemiol. 2010 Aug;63(8):883-9120079607
Cites: Nuklearmedizin. 2010;49(5):195-20120838734
Cites: J Nucl Med. 2010 Nov;51(11):1813-2021051652
Cites: J Clin Oncol. 2011 Jan 10;29(2):186-9121149653
Cites: Nucl Med Commun. 2011 Mar;32(3):168-7621076343
Cites: Eur Urol. 2011 Jan;59(1):61-7121056534
Cites: Nucl Med Commun. 2012 Apr;33(4):384-9422367858
Cites: Mol Imaging Biol. 2012 Apr;14(2):252-921479710
Cites: BMJ. 2012;345:e671723097549
Cites: J Nucl Med. 2013 Apr;54(4):590-923482667
Cites: Jpn J Radiol. 2013 Apr;31(4):262-923377765
Cites: Nucl Med Commun. 2013 Oct;34(10):935-4523903557
Cites: Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):59-6723974666
Cites: Clin Nucl Med. 2014 Jan;39(1):26-3124217537
Cites: Urol Oncol. 2014 Jan;32(1):38.e17-2823769268
Cites: BMJ. 2014;348:f752424401467
PubMed ID
26753880 View in PubMed
Less detail

Combined CT-guided biopsy and cytology in diagnosis of bony lesions.

https://arctichealth.org/en/permalink/ahliterature24453
Source
Acta Radiol. 1992 May;33(3):225-9
Publication Type
Article
Date
May-1992
Author
T. Tikkakoski
S. Lähde
J. Puranen
M. Apaja-Sarkkinen
Author Affiliation
Department of Diagnostic Radiology, Oulu University Central Hospital, Finland.
Source
Acta Radiol. 1992 May;33(3):225-9
Date
May-1992
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Biopsy - methods
Bone Neoplasms - pathology - radiography
Comparative Study
Female
Humans
Male
Middle Aged
Tomography, X-Ray Computed
Abstract
The results of 44 trephine (OD 1.4-4 mm) biopsies and 39 fine needle (0.7-0.9 mm) aspirations of skeletal, mainly vertebral, lesions performed under CT-guidance in 54 patients were evaluated. The fine needle sample was aspirated through the trephine as a complementary procedure in 29 patients and a fine needle aspiration only was performed in 10 patients. Trephine biopsy only was performed in 15 patients. Sufficient material for histologic and cytologic analyses was obtained in 93% (41/44) and 97% (38/39) and a correct benign or malignant diagnosis was obtained in 84% (37/44) and 90% (35/39), respectively. Among the combined examinations the fine needle aspiration alone was diagnostic in 2 cases while the trephine specimen alone provided diagnostic material in 2 cases. In 24 cases both the cytologic and histologic samples were adequate for diagnostic purposes. In one case both methods gave false-negative results. The combined use of cytologic and histologic samples in CT-guided bone biopsies increased diagnostic accuracy. The aorta was perforated once with a 1.4-mm needle but without sequelae. CT-guided bone biopsy was found to be a safe, reliable and cost-efficient method.
PubMed ID
1591124 View in PubMed
Less detail